- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04882943
COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database (COREC)
Chronic cough (TC), defined by a duration exceeding 8 weeks, is a particularly frequent symptom with a prevalence observed at 9.6% 1. Chronic cough is the cause of a major handicap for patients with a impact on their quality of life 2.
Although CT is common, management is often delicate and complex. In studies, asthma, gastroesophageal reflux disease, posterior flushing, rhino-sinusitis, or taking tussigenic medications are common causes of chronic coughs. However, chronic refractory or unexplained cough, which corresponds to cough for which no cause has been found or the treatments directed against the cause of the cough have not made it possible to resolve the cough, is a real problem in practice. nick3.
There is currently no prospective data in France on the characteristics of chronic cough (etiologies, response to treatment) and the percentage of refractory cough.
The aim of the study is to constitute a French prospective multicenter hospital cohort of chronic cough patients in order to identify, for the first time in France in a prospective and multicenter manner, the frequency of patients with refractory cough among chronic cough patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Visit V1: Visit as part of the treatment After obtaining no objection, the patient will complete cough questionnaires
Visit V2: Visit as part of the treatment Visit carried out at 3 months with evaluation of the cough on the criteria of severity and quality of life. An evaluation of the response to treatments initiated at visit V1 will be carried out.
Visit V3: Visit as part of the treatment Visit carried out at 6 months either by telephone if response to treatment at 3 months (at the discretion of the investigators) or in the investigative center if no response to treatment at 3 months. An evaluation of the cough on the criteria of severity and quality of life will be performed.
Visit V4 to V8: Visit within the framework of research Phone call every 6 months made by a research technician. Patient severity and quality of life questionnaires will be issued in advance and completed at the time of telephone contact.
The end of research visit corresponds to the V8 visit.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Toulouse, France, 31059
- UHToulouse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥18 years old
- Consultation motivated by cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough)
- Patient covered by a National Health Insurance
Exclusion Criteria:
- Active smoker or recent smoking cessation (within the past 6 months)
- Intake of medications causing cough (the patient can be included 4 weeks after treatment discontinuation if cough persists)
- Pregnant or breast-feeding women
- Upper or lower respiratory tract infection within the past 4 weeks
- Active lung disease (such as interstitial lung disease, lung cancer, abnormal dilation of the bronchi).
- History of chronic bronchitis.
- Current treatment with an angiotensin converting enzyme (ACE) inhibitor
- History of cancer within the past 5 years or active cancer (excluding cutaneous squamous-cell carcinoma).
- Person not fluent in French
- Adult not able to express his/her consent verbally
- Patient refusal
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
patients with unexplained or refractory chronic cough
Patients with cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough)
|
Quality of life questionnaires
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
French prospective multicenter hospital cohort of chronic cough patients (requency of patients with unexplained or refractory chronic cough (URCC)
Time Frame: 24 months
|
set up a French prospective multicenter hospital cohort of chronic cough patients in order to identify the frequency of patients with unexplained or refractory chronic cough (URCC) for the first time in France
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Laurent GUILLEMINAULT, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/20/0378
- 2020-A02774-35 (OTHER: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Chronic Cough
-
Trevi TherapeuticsRecruitingRefractory Chronic CoughCanada, United Kingdom
-
Mayo ClinicRecruitingRefractory Chronic CoughUnited States
-
Bellus Health Inc. - a GSK companyRecruitingRefractory Chronic CoughKorea, Republic of, United States, Taiwan, Australia, New Zealand, Czechia, United Kingdom, Germany, Slovakia, India
-
Guangdong Hengrui Pharmaceutical Co., LtdEnrolling by invitationRefractory Chronic CoughChina
-
Bellus Health IncTerminatedChronic Refractory CoughUnited States, United Kingdom
-
Afferent Pharmaceuticals, Inc.CompletedRefractory Chronic Cough
-
Afferent Pharmaceuticals, Inc.CompletedRefractory Chronic Cough
-
Afferent Pharmaceuticals, Inc.Completed
-
The First Affiliated Hospital of Guangzhou Medical...Unknown
-
Patara PharmaCompletedRefractory Chronic CoughNetherlands, United Kingdom
Clinical Trials on questionnaires
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
Direction Centrale du Service de Santé des ArméesCompleted
-
Sun Yat-sen UniversityNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisRecruitingIntensive Care Unit Syndrome | Pediatric Post-intensive Care SyndromeFrance
-
University Hospital, GrenobleUniversity Grenoble AlpsNot yet recruitingChildhood Cancer | Adapted Physical ActivityFrance
-
M.D. Anderson Cancer CenterCompletedAdvanced Cancer | Malignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
The University of Hong KongCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
Cliniques universitaires Saint-Luc- Université...Fonds National de la Recherche ScientifiqueNot yet recruitingAlcohol Use Disorder
-
Memorial Sloan Kettering Cancer CenterIcahn School of Medicine at Mount Sinai; Hackensack Meridian Health; Derald H...CompletedLeukemia | Multiple Myeloma | Non-Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States